文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

伏立康唑治疗肝衰竭患者侵袭性肺曲霉病的疗效与安全性:随机对照临床试验研究方案

Efficacy and safety of voriconazole in the treatment of invasive pulmonary aspergillosis in patients with liver failure: study protocol for a randomized controlled clinical trial.
PubMed 文献 · Trials · 2023-12-17

本研究为一项非双盲随机对照试验,计划纳入96例慢加急性肝衰竭合并侵袭性肺曲霉病患者,按1:1随机接受优化伏立康唑方案或轻中度肝硬化(Child-Pugh A和B)推荐伏立康唑方案,随访8周,主要结局为伏立康唑抗真菌疗效,旨在为肝衰竭患者伏立康唑方案优化提供参考。

要点

  • 慢加急性肝衰竭患者易发生真菌感染,侵袭性肺曲霉病发病率增加。
  • 伏立康唑是侵袭性曲霉病一线抗真菌药,但重度肝硬化(Child-Pugh C)和肝衰竭患者尚无推荐。
  • 本试验比较优化伏立康唑方案与轻中度肝硬化推荐方案,主要结局为抗真菌疗效。

核心结论

  • 本试验旨在证明伏立康唑治疗肝衰竭患者侵袭性肺曲霉病的疗效与安全性,期望为科学优化伏立康唑方案提供参考,并为慢加急性肝衰竭合并侵袭性肺曲霉病的规范化治疗提供现实依据。

研究设计与样本

  • 本研究为非双盲随机对照试验,计划纳入96例符合条件的慢加急性肝衰竭合并侵袭性肺曲霉病患者,按1:1比例随机分配接受优化伏立康唑方案或轻中度肝硬化(Child-Pugh A和B)推荐伏立康唑方案,随访8周。

关键数值与推荐

  • 主要结局指标为伏立康唑抗真菌疗效。
  • 次要结局指标包括血浆伏立康唑谷浓度、实验室检查(CRP、PCT、ESR等)、胸部CT、不良事件以及第4周和第8周死亡率。
  • 伏立康唑被推荐为侵袭性曲霉病治疗的一线抗真菌药物;然而,对于重度肝硬化(Child-Pugh C)和肝衰竭患者,尚未给出推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute-on-chronic liver failure (ACLF) is a common clinical type of liver failure, and patients with acute-on-chronic liver failure are prone to fungal infections, especially the increasing incidence of invasive pulmonary aspergillosis (IPA). Voriconazole is recommended as the first-line antifungal agent in the treatment of invasive aspergillosis; however, no recommendation has been given for patients with severe liver cirrhosis (Child-Pugh C) and liver failure. This trial aims to examine the therapeutic effects and safety of voriconazole in the treatment of IPA in patients with liver failure. METHODS: This study is a non-double-blind randomized controlled trial. The 96 eligible acute-on-chronic liver failure patients complicated with invasive pulmonary aspergillosis will be randomly assigned to receive either the optimized voriconazole regimen or the recommended voriconazole regimen for patients with mild to moderate liver cirrhosis (Child-Pugh A and B), at a 1:1 ratio, with an 8-week follow-up period. The antifungal efficacy of voriconazole will be the primary outcome measure. Plasma voriconazole trough concentration, the laboratory examination (CRP, PCT, ESR, etc.), chest CT, adverse events, and mortality at week 4 and 8 will be the secondary outcome measures. DISCUSSION: This trial aims to demonstrate the efficacy and safety of voriconazole in the treatment of IPA in patients with liver failure, which is expected to provide a reference for scientific optimization of voriconazole regimens and a realistic basis for the standardized treatment of acute-on-chronic liver failure patients complicated with invasive pulmonary aspergillosis. TRIAL REGISTRATION: The trial was registered with the Chinese Clinical Trial Registry, ChiCTR2100048259. Registered on 5 July 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Yu X, Xu L, Zheng J, et al. Efficacy and safety of voriconazole in the treatment of invasive pulmonary aspergillosis in patients with liver failure: study protocol for a randomized controlled clinical trial. Trials. 2023. PMID: 38105213. doi:10.1186/s13063-023-07755-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。